PAH is a progressive disease characterised by the narrowing of blood vessels in the lungs, making it increasingly difficult for the heart to pump blood. Diagnosis is key, as pulmonary hypertension comprises five major types, each requiring a distinct treatment approach. Conventional PAH therapies, such as vasodilators, work by relaxing blood vessels for circulation. Sotatercept, however, functions by restoring the balance of proteins that regulate blood vessel growth and repair. This mechanism may help address vessel thickening and stiffness, supporting long-term management beyond symptom relief.

Dr Edgar Tay and Dr Abdul Razakjr Bin Omar, cardiologists at Mount Elizabeth Hospital, recently shared the journey of a 49-year-old female patient who had been living with PAH for over a decade. In recent months, her symptoms worsened, limiting treatment options and affecting her daily activities. Following the administration of Sotatercept, she experienced measurable benefits, including increased oxygen levels, reduced breathlessness, and more tolerance for travel.

With ongoing developments in cardiology, medical specialists continue to explore treatment approaches for complex cardiovascular conditions. The introduction of Sotatercept provides another option in PAH management, supporting efforts for patient care and quality of life.